Prasugrel STEMI subgroup analysis

The Lancet

Volumn 373, Issue 9678, 2009, Pages 1845-1846

  Floyd, James ^a   Wolfe, Sidney ^a  

^a Public Citizen   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HEART ENZYME; PRASUGREL;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOT LYSIS; CORONARY ARTERY BYPASS GRAFT; FOOD AND DRUG ADMINISTRATION; HAZARD RATIO; HEART INFARCTION; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 66149130658     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61019-9     Document Type: Letter

References (4)

1. Montalescot G., Wiviott S.D., Braunwald E., et al., for the TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373 (2009) 723-731
2. FDA. Briefing materials from Feb 3, 2009, meeting of FDA Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4412b1-01-FDA.pdf (accessed March 20, 2009).
3. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
4. Wiviott S.D., Antman E.M., Gibson C.M., et al., for the TRITON-TIMI 38 investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 152 (2006) 627-635